Calogero D'Alessandria

university of munich

H指数:29

被引数:3,231

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Navigating the safety profile of Actinium-225 targeted alpha therapy: a comprehensive review

导航锕225靶向 α 治疗的安全性: 一项综合综述

Clinical and Translational Imaging

IF1.6

2025-11-010

Preclinical evaluation of [68Ga]Ga-AAZTA-FAPI-46: a novel PET tracer for targeting fibroblast activation protein (FAP)

[68Ga]Ga-AAZTA-FAPI-46的预临床评价：一种靶向成纤维细胞活化蛋白（FAP）的新型PET示踪剂

EJNMMI Radiopharmacy and Chemistry

IF3.3

2025-08-050

OAAI

Biochemical failure-free survival of 18F-rhPSMA-7 and 18F-flotufolastat PET-guided salvage radiotherapy for patients with recurrent prostate cancer

SCIENTIFIC REPORTS

IF3.9

2025-01-170

OAAI

CXCR4-directed endoradiotherapy with [177Lu]Pentixather added to total body irradiation for myeloablative conditioning in patients with relapsed/refractory acute myeloid leukemia

CXCR4靶向内放射治疗联合[177Lu]Pentixather用于大剂量骨髓清除性预处理，治疗复发/难治性急性髓系白血病患者

THERANOSTICS

IF13.3

2025-01-012

PRE

Influence of fasting prior to 18F-rhPSMA-7.3 (Flotufolastat F-18) PET/CT on biodistribution and tumor uptake

EJNMMI RESEARCH

IF3

2024-11-120

OAAI

Matched-pair analysis of mCRPC patients receiving 177Lu-labeled PSMA-targeted radioligand therapy in a 4-week versus 6-week treatment interval

EJNMMI RESEARCH

IF3

2024-10-140

OAAI

Pre-therapy PET-based voxel-wise dosimetry prediction by characterizing intra-organ heterogeneity in PSMA-directed radiopharmaceutical theranostics

European Journal of Nuclear Medicine and Molecular Imaging

IF7.6

2024-05-091

OAAI

Galectin-3 and cancer immunotherapy: a glycobiological rationale to overcome tumor immune escape

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

IF12.8

2024-02-064

OAAI

Improved Quality of Life in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Consecutive Cycles of 177Lu-PSMA I&T

JOURNAL OF NUCLEAR MEDICINE

IF9.1

2023-09-071

Safety and Efficacy of [177Lu]-PSMA-I&T Radioligand Therapy in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Report on 80 Patients over the Age of 80 Years

JOURNAL OF NUCLEAR MEDICINE

IF9.1

2023-06-155

The Impact of PSMA PET-Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy

JOURNAL OF NUCLEAR MEDICINE

IF9.1

2023-06-087

Prognostic Role of 68Ga-PSMA11 PET-Based Response in Patients with Prostate Cancer Undergoing Taxane-Based Chemotherapy

JOURNAL OF NUCLEAR MEDICINE

IF9.1

2022-12-298

177Lu-PSMA-I&T for Treatment of Metastatic Castration-Resistant Prostate Cancer: Prognostic Value of Scintigraphic and Clinical Biomarkers

177Lu-PSMA-I & T用于治疗转移性去势抵抗性前列腺癌: 闪烁显像和临床生物标志物的预后价值

JOURNAL OF NUCLEAR MEDICINE

IF9.1

2022-09-2221

Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review

FRONTIERS IN MEDICINE

IF3

2022-04-1215

OAAI

Preclinical biodistribution and dosimetry and human biodistribution comparing 18F-rhPSMA-7 and single isomer 18F-rhPSMA-7.3

EJNMMI RESEARCH

IF3

2022-02-045

OAAI

Promise and challenges of clinical non-invasive T-cell tracking in the era of cancer immunotherapy

EJNMMI RESEARCH

IF3

2022-01-3110

OAAI

Synthesis and Preclinical Evaluation of 177Lu-Labeled Radiohybrid PSMA Ligands for Endoradiotherapy of Prostate Cancer

JOURNAL OF NUCLEAR MEDICINE

IF9.1

2022-01-2724

OAAI

A Semi Rigid Novel Hydroxamate AMPED-Based Ligand for 89Zr PET Imaging

MOLECULES

IF4.6

2021-09-255

OAAI

Pretherapeutic Comparative Dosimetry of 177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer

JOURNAL OF NUCLEAR MEDICINE

IF9.1

2021-09-1620

Effective rational humanization of a PASylated anti-galectin-3 Fab for the sensitive PET imaging of thyroid cancer in vivo

SCIENTIFIC REPORTS

IF3.9

2021-04-017

OAAI

Calogero D'Alessandria

个人简介

教育背景

工作经历

荣誉奖项

研究方向